Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug release capacities for delivery of curcumin to colitis tissues-Reference-Cited by-同舟云学术

Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug release capacities for delivery of curcumin to colitis tissues

Published:2021 Issue:6 Volume:9 Page:1604-1615
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Huang Yamei¹²³⁴⁵,Canup Brandon S. B.⁶⁷⁸⁹,Gou Shuangquan¹⁰¹¹⁴⁵¹²,Chen Nanxi¹²³⁴⁵,Dai Fangyin¹²³⁴⁵,Xiao Bo¹²³⁴⁵^ORCID,Li Changming¹⁰¹¹⁴⁵¹²^ORCID

Affiliation:

1. State Key Laboratory of Silkworm Genome Biology

2. College of Sericulture

3. Textile and Biomass Sciences

4. Southwest University

5. Chongqing 400715

6. Department of Chemistry

7. Georgia State University

8. Atlanta

9. USA

10. Chongqing Key Laboratory of Soft-Matter Material Chemistry and Function Manufacturing

11. School of Materials and Energy

12. P. R. China

Abstract

Pluronic F127 and catalase facilitated the accumulation and drug release of nanoparticles in colitis tissues, and improved their therapeutic outcomes.

Funder

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Venture and Innovation Support Program for Chongqing Overseas Returnees

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2021/TB/D0TB02092C

Reference47 articles.

1. Inflammation and the Intestinal Barrier: Leukocyte–Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair

2. The emerging role of histologic disease activity assessment in ulcerative colitis

3. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

4. Management of Steroid-Dependent Ulcerative Colitis: Immunomodulatory Agents, Biologics, or Surgery?

5. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments and new directions in the use of natural products for the treatment of inflammatory bowel disease;Phytomedicine;2024-09

2. Natural dietary ROS scavenger-based nanomaterials for ROS-related chronic disease prevention and treatment;Chemical Engineering Journal;2024-06

3. Dual‐ROS Sensitive Moieties Conjugate Inhibits Curcumin Oxidative Degradation for Colitis Precise Therapy;Advanced Healthcare Materials;2024-03-03

4. Hyaluronic acid-functionalized DDAB/PLGA nanoparticles for improved oral delivery of magnolol in the treatment of ulcerative colitis;International Journal of Pharmaceutics;2024-03

5. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances;Journal of Materials Chemistry B;2024